Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition

Francesca R. Fusco, Serenella Anzilotti, Carmela Giampà, Clemente Dato, Daunia Laurenti, Alessandro Leuti, Luca Colucci D'Amato, Lorena Perrone, Giorgio Bernardi, Mariarosa A B Melone

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The mitogen-activated protein kinases (MAPKs) superfamily comprises three major signaling pathways: the extracellular signal-regulated protein kinases (ERKs), the c-Jun N-terminal kinases or stress-activated protein kinases (JNKs/SAPKs) and the p38 family of kinases.ERK 1/2 signaling has been implicated in a number of neurodegenerative disorders, including Huntington's disease (HD). Phosphorylation patterns of ERK 1/2 and JNK are altered in cell models of HD. In this study, we aimed at studying the correlations between ERK 1/2 and the neuronal vulnerability to HD degeneration in the R6/2 transgenic mouse model of HD. Single and double-label immunofluorescence for phospho-ERK (pERK, the activated form of ERK) and for each of the striatal neuronal markers were employed on perfusion-fixed brain sections from R6/2 and wild-type mice. Moreover, Phosphodiesterase 4 inhibition through rolipram was used to study the effects on pERK expression in the different types of striatal neurons. We completed our study with western blot analysis. Our study shows that pERK levels increase with age in the medium spiny striatal neurons and in the parvalbumin interneurons, and that rolipram counteracts such increase in pERK. Conversely, cholinergic and somatostatinergic interneurons of the striatum contain higher levels of pERK in the R6/2 mice compared to the controls. Rolipram induces an increase in pERK expression in these interneurons. Thus, our study confirms and extends the concept that the expression of phosphorylated ERK 1/2 is related to neuronal vulnerability and is implicated in the pathophysiology of cell death in HD.

Original languageEnglish
Pages (from-to)225-233
Number of pages9
JournalNeurobiology of Disease
Volume46
Issue number1
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Type 4 Cyclic Nucleotide Phosphodiesterase
Mitogen-Activated Protein Kinase 3
Huntington Disease
Protein Kinases
Phosphotransferases
Rolipram
Corpus Striatum
Extracellular Signal-Regulated MAP Kinases
Interneurons
Neurons
Parvalbumins
Inhibition (Psychology)
JNK Mitogen-Activated Protein Kinases
Heat-Shock Proteins
Mitogen-Activated Protein Kinases
Neurodegenerative Diseases
Cholinergic Agents
Transgenic Mice
Fluorescent Antibody Technique
Cell Death

Keywords

  • ERK
  • Huntington's disease
  • Immunohistochemistry
  • R6/2
  • Rolipram

ASJC Scopus subject areas

  • Neurology

Cite this

Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition. / Fusco, Francesca R.; Anzilotti, Serenella; Giampà, Carmela; Dato, Clemente; Laurenti, Daunia; Leuti, Alessandro; Colucci D'Amato, Luca; Perrone, Lorena; Bernardi, Giorgio; Melone, Mariarosa A B.

In: Neurobiology of Disease, Vol. 46, No. 1, 04.2012, p. 225-233.

Research output: Contribution to journalArticle

Fusco, Francesca R. ; Anzilotti, Serenella ; Giampà, Carmela ; Dato, Clemente ; Laurenti, Daunia ; Leuti, Alessandro ; Colucci D'Amato, Luca ; Perrone, Lorena ; Bernardi, Giorgio ; Melone, Mariarosa A B. / Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition. In: Neurobiology of Disease. 2012 ; Vol. 46, No. 1. pp. 225-233.
@article{406f04c223d8450a9cbbe21032b750ca,
title = "Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition",
abstract = "The mitogen-activated protein kinases (MAPKs) superfamily comprises three major signaling pathways: the extracellular signal-regulated protein kinases (ERKs), the c-Jun N-terminal kinases or stress-activated protein kinases (JNKs/SAPKs) and the p38 family of kinases.ERK 1/2 signaling has been implicated in a number of neurodegenerative disorders, including Huntington's disease (HD). Phosphorylation patterns of ERK 1/2 and JNK are altered in cell models of HD. In this study, we aimed at studying the correlations between ERK 1/2 and the neuronal vulnerability to HD degeneration in the R6/2 transgenic mouse model of HD. Single and double-label immunofluorescence for phospho-ERK (pERK, the activated form of ERK) and for each of the striatal neuronal markers were employed on perfusion-fixed brain sections from R6/2 and wild-type mice. Moreover, Phosphodiesterase 4 inhibition through rolipram was used to study the effects on pERK expression in the different types of striatal neurons. We completed our study with western blot analysis. Our study shows that pERK levels increase with age in the medium spiny striatal neurons and in the parvalbumin interneurons, and that rolipram counteracts such increase in pERK. Conversely, cholinergic and somatostatinergic interneurons of the striatum contain higher levels of pERK in the R6/2 mice compared to the controls. Rolipram induces an increase in pERK expression in these interneurons. Thus, our study confirms and extends the concept that the expression of phosphorylated ERK 1/2 is related to neuronal vulnerability and is implicated in the pathophysiology of cell death in HD.",
keywords = "ERK, Huntington's disease, Immunohistochemistry, R6/2, Rolipram",
author = "Fusco, {Francesca R.} and Serenella Anzilotti and Carmela Giamp{\`a} and Clemente Dato and Daunia Laurenti and Alessandro Leuti and {Colucci D'Amato}, Luca and Lorena Perrone and Giorgio Bernardi and Melone, {Mariarosa A B}",
year = "2012",
month = "4",
doi = "10.1016/j.nbd.2012.01.011",
language = "English",
volume = "46",
pages = "225--233",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition

AU - Fusco, Francesca R.

AU - Anzilotti, Serenella

AU - Giampà, Carmela

AU - Dato, Clemente

AU - Laurenti, Daunia

AU - Leuti, Alessandro

AU - Colucci D'Amato, Luca

AU - Perrone, Lorena

AU - Bernardi, Giorgio

AU - Melone, Mariarosa A B

PY - 2012/4

Y1 - 2012/4

N2 - The mitogen-activated protein kinases (MAPKs) superfamily comprises three major signaling pathways: the extracellular signal-regulated protein kinases (ERKs), the c-Jun N-terminal kinases or stress-activated protein kinases (JNKs/SAPKs) and the p38 family of kinases.ERK 1/2 signaling has been implicated in a number of neurodegenerative disorders, including Huntington's disease (HD). Phosphorylation patterns of ERK 1/2 and JNK are altered in cell models of HD. In this study, we aimed at studying the correlations between ERK 1/2 and the neuronal vulnerability to HD degeneration in the R6/2 transgenic mouse model of HD. Single and double-label immunofluorescence for phospho-ERK (pERK, the activated form of ERK) and for each of the striatal neuronal markers were employed on perfusion-fixed brain sections from R6/2 and wild-type mice. Moreover, Phosphodiesterase 4 inhibition through rolipram was used to study the effects on pERK expression in the different types of striatal neurons. We completed our study with western blot analysis. Our study shows that pERK levels increase with age in the medium spiny striatal neurons and in the parvalbumin interneurons, and that rolipram counteracts such increase in pERK. Conversely, cholinergic and somatostatinergic interneurons of the striatum contain higher levels of pERK in the R6/2 mice compared to the controls. Rolipram induces an increase in pERK expression in these interneurons. Thus, our study confirms and extends the concept that the expression of phosphorylated ERK 1/2 is related to neuronal vulnerability and is implicated in the pathophysiology of cell death in HD.

AB - The mitogen-activated protein kinases (MAPKs) superfamily comprises three major signaling pathways: the extracellular signal-regulated protein kinases (ERKs), the c-Jun N-terminal kinases or stress-activated protein kinases (JNKs/SAPKs) and the p38 family of kinases.ERK 1/2 signaling has been implicated in a number of neurodegenerative disorders, including Huntington's disease (HD). Phosphorylation patterns of ERK 1/2 and JNK are altered in cell models of HD. In this study, we aimed at studying the correlations between ERK 1/2 and the neuronal vulnerability to HD degeneration in the R6/2 transgenic mouse model of HD. Single and double-label immunofluorescence for phospho-ERK (pERK, the activated form of ERK) and for each of the striatal neuronal markers were employed on perfusion-fixed brain sections from R6/2 and wild-type mice. Moreover, Phosphodiesterase 4 inhibition through rolipram was used to study the effects on pERK expression in the different types of striatal neurons. We completed our study with western blot analysis. Our study shows that pERK levels increase with age in the medium spiny striatal neurons and in the parvalbumin interneurons, and that rolipram counteracts such increase in pERK. Conversely, cholinergic and somatostatinergic interneurons of the striatum contain higher levels of pERK in the R6/2 mice compared to the controls. Rolipram induces an increase in pERK expression in these interneurons. Thus, our study confirms and extends the concept that the expression of phosphorylated ERK 1/2 is related to neuronal vulnerability and is implicated in the pathophysiology of cell death in HD.

KW - ERK

KW - Huntington's disease

KW - Immunohistochemistry

KW - R6/2

KW - Rolipram

UR - http://www.scopus.com/inward/record.url?scp=84858151215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858151215&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2012.01.011

DO - 10.1016/j.nbd.2012.01.011

M3 - Article

C2 - 22311347

AN - SCOPUS:84858151215

VL - 46

SP - 225

EP - 233

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 1

ER -